Cipla Limited





Delayed NSE India Stock Exchange 06:43:29 2023-12-08 am EST Intraday chart for Cipla Limited 5-day change 1st Jan Change
1,219.1 INR -0.30% +1.11% +13.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cipla Unit Recalls Anti-Epileptic Drugs Due to Sachet Leaks MT
Cipla's Arm Acquires Additional 15% Stake in Joint Venture MT
Selling in IT Drags Indian Equities to Close Lower on Friday MT
INDIA STOCKS-Indian shares lacklustre as IT stocks snap rally RE
Indian Equities End Flat on Thursday, Weighed Down by Pharmaceutical, IT Stocks MT
Gains in Domestic Major Companies Push Indian Equities to Close Higher on Wednesday MT
Cipla Gets Warning Letter from US FDA After Pithampur, India Unit Inspection MT
INDIA STOCKS-Indian shares set for muted opening; TCS, Cipla in focus RE
Cipla Completes Sale of Entire Stake in Ugandan Subsidiary MT
India's Zydus Q2 profit jumps on strong domestic, US demand RE
India's Gland Pharma misses Q2 profit view on higher expenses RE
Nomura Adjusts Cipla's Price Target to INR1,353 from INR1,229, Keeps at Buy MT
Jefferies Downgrades Cipla to Hold From Buy, Adjusts Price Target to INR1,230 From INR1,210 MT
Cipla's Consolidated Net Profit Climbs in Fiscal Q2 MT
INDIA STOCKS-Financials lead slide in Indian shares; Reliance curbs losses RE
Transcript : Cipla Limited, Q2 2024 Earnings Call, Oct 27, 2023 CI
Indian drugmaker Cipla tops Q2 profit view on strong demand RE
Cipla Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Cipla Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Indian Equities End Lower for Fifth Straight Session on Israel-Hamas Conflict Worries MT
Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences CI
Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative CI
India's Torrent Pharma posts Q2 profit rise on strong demand RE
Indian Equities Fall on Wednesday Amid Intensifying Israel-Hamas Conflict MT
Cipla Arm Gets US FDA's Establishment Inspection Report After Inspection of New York Unit MT
Chart Cipla Limited
More charts
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Cipla Limited - NSE India Stock Exchange
  4. News Cipla Limited
  5. Nomura Adjusts Cipla's Price Target to INR1,036 From INR1,195, Keeps at Buy
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration